Intesti®-bacteriophage (Solution) Instructions for Use
Marketing Authorization Holder
Microgen NPO, JSC (Russia)
ATC Code
V03A (Other therapeutic agents)
Dosage Form
| Intesti®-bacteriophage | Oral and rectal solution: bottle 20 ml 4 or 10 pcs. or bottle 100 ml 1 pc. |
Dosage Form, Packaging, and Composition
| Solution for oral or rectal administration |
| A mixture of sterile filtrates of phagolysates of Shigella flexneri serovars 1, 2, 3, 4, 6, Shigella sonnei, Salmonella paratyphi A, Salmonella paratyphi B, Salmonella typhimurium, Salmonella infantis, Salmonella choleraesuis, Salmonella oranienburg, Salmonella enteritidis, enteropathogenic Escherichia coli of various serogroups, most significant in the etiology of enteral diseases, Proteus vulgaris, Proteus mirabilis, Enterococcus, Staphylococcus, Pseudomonas aeruginosa. |
Excipients: Chinosol 0.0001 g/ml
20 ml – bottles (4) – cardboard packs.
20 ml – bottles (10) – cardboard packs.
100 ml – bottles (1) – cardboard packs.
Clinical-Pharmacological Group
Immunobiological drug – bacteriophage
Pharmacotherapeutic Group
Absent
Pharmacological Action
The drug causes specific lysis of bacteria Shigella flexneri serovars 1, 2, 3, 4, 6, Shigella sonnei, Salmonella paratyphi A, Salmonella paratyphi B, Salmonella typhimurium, Salmonella infantis, Salmonella choleraesuis, Salmonella oranienburg, Salmonella enteritidis, Escherichia coli, Proteus vulgaris, Proteus mirabilis, Enterococcus, Staphylococcus, Pseudomonas aeruginosa.
Indications
Treatment and prevention of gastrointestinal diseases caused by bacteria of dysentery, Salmonella spp., Escherichia coli, Proteus spp., Enterococcus spp., Staphylococcus spp., Pseudomonas aeruginosa or their combination
- Bacterial dysentery;
- Salmonellosis;
- Dyspepsia;
- Dysbacteriosis;
- Enterocolitis, colitis.
An important condition for effective phage therapy is the preliminary determination of the phage sensitivity of the pathogen.
ICD codes
| ICD-10 code | Indication |
| A02 | Other salmonella infections |
| A03 | Shigellosis |
| A04.0 | Enteropathogenic Escherichia coli infection |
| A05.0 | Staphylococcal food poisoning |
| B95.6 | Staphylococcus aureus as the cause of diseases classified to other chapters |
| B95.7 | Other staphylococci as the cause of diseases classified to other chapters |
| B96.4 | Proteus (mirabilis) (morganii) as the cause of diseases classified in other chapters |
| B96.5 | Pseudomonas (aeruginosa) (mallei) (pseudomallei) as the cause of diseases classified in other chapters |
| K30 | Functional dyspepsia (digestive disorder) |
| K63 | Other diseases of intestine |
| ICD-11 code | Indication |
| 1A02 | Intestinal infections due to Shigella |
| 1A03.0 | Infection due to enteropathogenic strains of Escherichia coli |
| 1A09.Z | Salmonella infection, unspecified |
| 1A10 | Staphylococcal food poisoning |
| 1B5Y | Other specified staphylococcal or streptococcal diseases |
| DB31.Z | Other acquired anatomical changes of the colon, unspecified |
| DD90.0 | Globus sensation |
| DD90.1 | Functional dysphagia |
| DD90.3 | Functional dyspepsia |
| DD90.Z | Functional disorders of esophagus or gastroduodenal system, unspecified |
| DE2Z | Diseases of the digestive system, unspecified |
| XN022 | Pseudomonas |
| XN09P | Staphylococcus leei |
| XN0H1 | Staphylococcus capitis |
| XN0PR | Staphylococcus auricularis |
| XN2GD | Staphylococcus haemolyticus |
| XN2HN | Staphylococcus sciuri |
| XN3BS | Proteus |
| XN4C9 | Staphylococcus warneri |
| XN4N7 | Staphylococcus lugdunensis |
| XN6BM | Staphylococcus aureus |
| XN6FH | Staphylococcus pettenkoferi |
| XN7RE | Staphylococcus simulans |
| XN7TQ | Staphylococcus xylosus |
| XN8KJ | Staphylococcus epidermidis |
| XN8WC | Staphylococcus pasteuri |
| XN95B | Staphylococcus cohnii |
| XN99G | Staphylococcus caprae |
| XN9X8 | Staphylococcus schleiferi |
| XN9ZG | Staphylococcus |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
The drug is intended for oral and rectal administration. For treatment, the drug is taken orally 4 times a day 0.5-1 hour before meals from the first day of illness for 7-10 days.
For infants in the first months of life, during the first two days of administration, the drug is diluted twice with boiled water; in the absence of adverse reactions (regurgitation, skin rashes), the bacteriophage can subsequently be used undiluted.
The drug is administered orally 3 times a day 30 minutes before feeding. In cases of uncontrollable vomiting, the drug is administered in the form of high enemas (via a gas outlet tube or catheter) daily.
A combination of rectal (in the form of high enemas) and oral administration of the drug is possible. The course of treatment is 7-10 days.
Recommended dosages of the drug
| Age | Dose per 1 administration (ml) | |
| orally | rectally | |
| 0-6 months | 5 | 10 |
| 6-12 months | 10-15 | 20 |
| 1 to 3 years | 15-20 | 20-30 |
| 3 to 8 years | 20-30 | 30-40 |
| 8 years and older | 30-40 | 50-60 |
In the absence of colitic syndrome, it is recommended to replace one oral administration with a single rectal administration of a single age dose of the drug in the form of an enema after bowel movement.
For prophylactic purposes, the optimal regimen is daily administration of a single age dose. The duration of the drug administration is determined by the conditions of the epidemic situation.
Adverse Reactions
In infants during the first 2 days of drug administration, regurgitation and skin rashes are possible.
Contraindications
- Hypersensitivity to the components of the drug.
Use in Pregnancy and Lactation
The use of this medicinal product during pregnancy and breastfeeding is possible in the presence of infections caused by phage-sensitive strains of bacteria (as recommended by a doctor).
Pediatric Use
It is prescribed to infants in the first months of life.
Special Precautions
Do not use the drug if it is cloudy!
Due to the content of a nutrient medium in the drug, in which bacteria from the environment can develop, causing cloudiness of the drug, the following rules must be observed when opening the vial
- Wash hands thoroughly;
- Treat the cap with an alcohol-containing solution;
- Remove the cap without opening the stopper;
- Do not place the stopper with the inner surface on the table or other objects;
- Do not leave the vial open;
- Store the opened vial only in the refrigerator.
When using small doses (2-8 drops), the drug must be drawn with a sterile syringe in a volume of 0.5-1 ml.
The drug from an opened vial, subject to storage conditions, the above rules and the absence of cloudiness, can be used throughout the entire shelf life.
Information on the possible effect of the medicinal product on the ability to drive vehicles and mechanisms.
Absent.
Overdose
Symptoms of overdose have not been established.
Drug Interactions
The use of the drug is possible in combination with other medicinal products, including antibiotics.
Storage Conditions
Transport in accordance with SP 3.3.2.1248-03 at a temperature of 2 to 8°C (46.4°F). Transportation at a temperature of 8 to 25°C (77°F) for no more than 1 month is allowed.
The drug should be stored in accordance with SP 3.3.2.1248-03 in a dry, light-protected place, out of the reach of children, at a temperature of 2 to 8°C (46.4°F).
Shelf Life
Shelf life – 2 years. Do not use the drug after the expiration date.
Dispensing Status
Available without a prescription.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer